Sign in
Not yet recruitingNo phase

Whole-body PET/CT scanning to image inflammation in large vessel vasculitis

Tests a newer whole-body PET/CT scanner in adults with large vessel vasculitis.

Key facts

Who runs it
Imperial College London
Where
United Kingdom3 sites in 1 countryChoose a country to see its sites
Trial code
Registry title
Long-Axial Field of View (LAFOV) [18F]FDG PET/CT Imaging in Large Vessel Vasculitis (LVV): Protocol Optimisation Study.
Status
Not yet recruiting
People taking part
18 people, planned
Starts
1 Dec 2026
Expected to end
1 Jan 2028
Type of study
Interventional, 2 groups
Treatments tested
  • [18F]FDG Long-Axial Field of View (LAFOV)-PET/CT
  • CT Angiogram
  • MR Angiogram
Record updated
16 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults newly diagnosed with large vessel vasculitis, an inflammation of the body's main arteries. It also takes a small number of healthy volunteers. Both groups get whole-body PET/CT scans.

Age
18 years and older. Healthy volunteers: three aged 18 to under 50, and three aged 50 or older.
Sex
All sexes
Disease stage
Patients: newly diagnosed large vessel vasculitis, by the 2022 ACR/EULAR criteria or by clear findings on standard imaging. WHO performance status 0-2, meaning able to care for yourself.
Earlier treatment
Patients cannot join if they started steroids more than 7 days before the scan tracer is given. Healthy volunteers cannot ever have taken steroids, blood pressure medicine or antipsychotic medicine.
Biomarker or test result
Patients with a history of kidney problems, kidney transplant or diabetes need an eGFR (kidney function test) of 30 (mL/min/1.73m2) or more within 3 months of the scan.

Main reasons for not taking part

  • Pregnant or breastfeeding
  • Fear of closed spaces, or unable to lie through the scan
  • Patients: allergy to iodine contrast dye, or poorly controlled diabetes with blood sugar >11mmol/L (198 mg/dL)
  • Healthy volunteers: smoking history, weight of 75Kg (165 lb (75 kg)) or more, or kidney disease, diabetes, atrial fibrillation, migraines, rheumatoid arthritis or SLE
  • Healthy volunteers: any scan with radiation in the last 12 months, or cannot have MRI or gadolinium contrast

The registry criteria, word for word

Show all 32 criteriaShow less

Who can take part

  • ≥18 years of age
  • Newly diagnosed LVV (based on the 2022 American College of Rheumatology (ACR) and European Alliance of Associations for Rheumatology (EULAR) classification criteria or from a definite diagnosis of LVV on standard of care imaging)
  • WHO performance status 0-2
  • The subject is able and willing to comply with study procedures and signed and dated informed consent is obtained
  • eGFR of ≥30 (mL/min/1.73m2) within 3 months of [18F]FDG injection in subjects who have a history of renal impairment, renal disease, renal transplant or diabetes
  • Three subjects ≥18 years of age that are also < 50 years old and three subjects ≥50 years of age
  • WHO performance status 0-2
  • The subject is able and willing to comply with study procedures and signed and dated informed consent is obtained

Who cannot take part

  • Commencement of steroids > 7 days prior to administration of the radiotracer
  • Historic or current prescription of the following medications:
  • Any blood pressure medication
  • Any antipsychotic medication
  • Steroids
  • Weight of ≥75Kg (in order to keep the radiation dose <10mSV for HV)
  • Participants that have undergone any imaging investigation that exposes them to radiation within the previous 12 months
  • History of allergy to iodinated contrast
  • Known allergy to gadolinium-based contrast agents
  • History of smoking
  • History or current diagnosis of the following medical conditions:
  • Renal impairment, renal disease, renal transplant or diabetes mellitus
  • Evidence of any significant medical condition which, in the opinion of the Investigator, makes it undesirable for the HV to participate in the trial
  • Poorly controlled diabetic with a blood glucose >11mmol/L
  • Evidence of a significant medical condition or laboratory finding which, in the opinion of the Investigator, makes it undesirable for the patient to participate in the trial
  • The subject is pregnant or lactating
  • Participants with claustrophobia or who are unable to comfortably tolerate the scanning procedure
  • The subject is pregnant or lactating
  • Participants with claustrophobia or who are unable to comfortably tolerate the scanning procedure
  • Participants with any contra-indication to MRI
  • Atrial Fibrillation
  • Migraines
  • Rheumatoid Arthritis
  • Systemic Lupus Erythematosus (SLE)

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Large vessel vasculitis (LVV) is an autoimmune inflammatory disorder affecting the major arteries of the body. The diagnosis and monitoring this condition can be challenging, as patients often present with symptoms that are unclear, and the diagnostic criteria currently used are varied. Accurate diagnosis is essential because it helps to tailor the treatment to each patient. Some treatments, such as steroids and immunosuppressive medications, can have significant side effects, so they need to be used carefully and only when truly needed.

Read full original descriptionShow less

An [18F]FDG Positron Emission Tomography/Computed Tomography (PET/CT) involves the injection of a small amount of radiolabelled sugar, which assesses glucose metabolism within the body. [18F]FDG PET/CT is already used by the NHS to detect inflammation within the vessel walls and diagnose LVV. Current diagnostic criteria for LVV largely rely on visual assessment by a radiologist. This approach therefore has limitations and may not fully capture changes in the levels of inflammation over time.

A new generation of scanners, known as Long Axial Field-of-View (LAFOV)-PET/CT or Total Body PET, are currently transforming what is possible in the field of medical imaging. These LAFOV-PET/CT scanners have new digital detectors that are more sensitive, produce sharper images, and can scan the entire body rapidly. This offers several potential advantages for patients with LVV, including the clearer detection of vessel wall inflammation, the ability to administer lower doses of the radiolabelled sugar ([18F]FDG), and the ability to take repeated pictures over time to measure subtle changes in blood flow and inflammation. Patients receiving a routine NHS [18F]FDG PET/CT scan for LVV are typically scanned 60 minutes after injection of the radiotracer using a standard PET/CT. Another benefit of LAFOV-PET/CT scanners is their ability to assess the amount of the radiolabelled sugar taken up by the whole body almost as soon as it is injected which could give important additional information.

As part of the LAVA-FLOW study we are planning to combine LAFOV-PET/CT with a CT Angiogram (CTA) in patients with LVV. A CTA is a scan that shows doctors what your blood vessels look like. It involves the injection of a dye into a vein that makes your blood vessels visible, highlighting vessel wall inflammation and vessel wall narrowing. This combination of LAFOV-PET/CT and CTA therefore has the potential to give a much more detailed picture of LVV than is achievable using current methods.

The LAVA-FLOW study therefore aims to develop a standardised protocol to be used in different hospital centres across the UK for the imaging of LVV using LAFOV-PET/CT. We also hope that the results of this particular study could lead to further larger studies with the potential to update the diagnostic criteria and improve the monitoring of this condition.

The 2 groups in the trial

  • LVV Patients: [18F]LAFOV-PET/CT & CT AngiogramTreatment being tested

    Treatment: [18F]FDG Long-Axial Field of View (LAFOV)-PET/CT and CT Angiogram

  • Healthy Volunteers: [18F]LAFOV-PET/CT & MR AngiogramTreatment being tested

    Treatment: [18F]FDG Long-Axial Field of View (LAFOV)-PET/CT and MR Angiogram

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Long-Axial Field of View (LAFOV) [18F]FDG PET/CT Imaging in Large Vessel Vasculitis (LVV): Protocol Optimisation Study.
Plain-language title
Whole-body PET/CT scanning to image inflammation in large vessel vasculitisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
16 October 2026